TABLE 1.

A comparative table of patients' characteristics with significance in differences

Characteristic	2019 (n = 223)	2020 (n = 150)	Significance
Mean age (SD)	67.2 (11.4)	66.0 (11.1)	0.313
Gender (% of cohort)			0.770
Male	165 (74%)	113 (75.3%)
Female	58 (26%)	37 (24.7%)
Primary malignancy (% of cohort)
Oropharynx	87 (39.0%)	44 (29.3%)	0.055
Oral cavity	57 (25.6%)	35 (23.3%)	0.625
Larynx	47 (21.1%)	29 (19.3%)	0.697
Hypopharynx	15 (6.7%)	25 (16.7%)	0.003
Nasopharynx	3 (1.3%)	2 (1.3%)	1.000
Others	14 (5.2%)	14 (9.3%)	0.210
TNM staging, AJCC seventh edition (% of cohort)
T0	4 (1.8%)	5 (3.4%)	0.493
T1	81 (36.3%)	37 (25.0%)	0.022
T2	57 (25.6%)	27 (18.2%)	0.099
T3	32 (14.3%)	25 (16.9%)	0.506
T4	49 (22.0%)	54 (36.5%)	0.002
N0	100 (44.8%)	58 (38.9%)	0.258
N1	12 (5.4%)	10 (6.7%)	0.594
N2	105 (47.1%)	74 (49.7%)	0.626
N3	6 (2.7%)	7 (4.7%)	0.302
M			0.296
0	217 (97.3%)	141 (95.3%)
1	6 (2.7%)	7 (4.7%)
Overall staging, AJCC seventh edition (% of cohort)
I	26 (25.1%)	21 (14.0%)	0.009
II	18 (8.1%)	9 (6.0%)	0.449
III	21 (9.4%)	18 (12.0%)	0.424
IV	128 (57.4%)	101 (67.3%)	0.053
IVa	109 (48.9%)	76 (50.7%)	0.735
IVb	13 (5.8%)	20 (13.3%)	0.012
IVc	6 (2.7%)	5 (3.3%)	0.761
Treatment intent
Radical	190 (85.2%)	118 (78.7%)
Palliative	33 (14.8%)	32 (21.3%)
Treatment modality
Radical surgery only	69 (30.9%)	30 (20.0%)	0.023
Surgery + adjuvant (chemo)radiotherapy	48 (23.5%)	40 (26.7%)	0.752
Radical (chemo)radiotherapy	67 (30.0%)	47 (31.3%)	0.876
Palliative radiotherapy	19 (8.5%)	15 (10.0%)	0.626
Palliative chemotherapy	0	1 (0.7%)	0.402
Best supportive care	16 (7.2%)	13 (8.7%)	0.598

Bold values indicate significant differences (p < 0.05).